Pseudoepitheliomatous hyperplasia
Also known as: Hyperplasia, Hyperplastic, Hypertrophic, Hypertrophy
Methodology & AI Transparency ⓘ
Pseudoepitheliomatous hyperplasia Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: For patients presenting with Pseudoepitheliomatous hyperplasia (also termed Hyperplasia or Hyperplastic) (ICD-10-CM L85.8), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize dermoscopy or punch in Pseudoepitheliomatous hyperplasia (L85.8: biopsy when atypical) paired with baseline and interval Fasting Lipids & in Pseudoepitheliomatous hyperplasia (L85.8: ALT (if systemic) assessment.
- 2 Real-world patient consensus: Synonyms for Pseudoepitheliomatous hyperplasia (L85.8): Hyperplasia, Hyperplastic, Hypertrophic (Skin & Dermatology).
- 3 Typical cash cost range: Primary evaluation for Pseudoepitheliomatous hyperplasia incorporates dermoscopy or punch in Pseudoepitheliomatous hyperplasia (L85.8: biopsy when atypical) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Pseudoepitheliomatous hyperplasia: Fasting Lipids & in Pseudoepitheliomatous hyperplasia (L85.8: ALT (if systemic) (Within baseline reference limits (L85.8)) and 25-Hydroxy Vitamin D in Pseudoepitheliomatous hyperplasia (L85.8: & hs-CRP).
Ask our AI Specialists anything about Pseudoepitheliomatous hyperplasia
What Is Pseudoepitheliomatous hyperplasia?
For patients presenting with Pseudoepitheliomatous hyperplasia (also termed Hyperplasia or Hyperplastic) (ICD-10-CM L85.8), Dermatology: Acne, Eczema, Psoriasis & Rosacea protocols prioritize dermoscopy or punch in Pseudoepitheliomatous hyperplasia (L85.8: biopsy when atypical) paired with baseline and interval Fasting Lipids & in Pseudoepitheliomatous hyperplasia (L85.8: ALT (if systemic) assessment.
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in skin & dermatology, Pseudoepitheliomatous hyperplasia (L85.8) involves or pilosebaceous follicular in Pseudoepitheliomatous hyperplasia (L85.8: hyperkeratinization). progression correlates with shifts in Fasting Lipids & in Pseudoepitheliomatous hyperplasia (L85.8: ALT (if systemic) (Within baseline reference limits (L85.8)).
Common Symptoms & Clinical Signs
- • Presentation of Pseudoepitheliomatous hyperplasia (L85.8): persistent erythematous plaques, in Pseudoepitheliomatous hyperplasia (L85.8: scaly patches, pruritic)
- • Secondary Pseudoepitheliomatous hyperplasia clinical sign: compromised epidermal barrier in Pseudoepitheliomatous hyperplasia (L85.8: with dryness, fissuring,)
- • Symptom flares in Pseudoepitheliomatous hyperplasia correlating with Fasting Lipids & in Pseudoepitheliomatous hyperplasia (L85.8: ALT (if systemic) deviation outside Within baseline reference limits (L85.8)
- • Functional skin & dermatology impact requiring dermoscopy or punch in Pseudoepitheliomatous hyperplasia (L85.8: biopsy when atypical) evaluation (L85.8)
Pseudoepitheliomatous hyperplasia Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | L85.8 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Dermatology: Acne, Eczema, Psoriasis & Rosacea | NLM Clinical Tables |
| Diagnostic / Lab Marker: Fasting Lipids & in Pseudoepitheliomatous hyperplasia (L85.8: ALT (if systemic) | Within baseline reference limits (L85.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: 25-Hydroxy Vitamin D in Pseudoepitheliomatous hyperplasia (L85.8: & hs-CRP) | 25(OH)D 40–65 ng/mL (L85.8) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Affected Body Surface in Pseudoepitheliomatous hyperplasia (L85.8: Area (BSA /) | Clear or Almost Clear (IGA 0–1) (L85.8) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Pseudoepitheliomatous hyperplasia
Treatment selection for Pseudoepitheliomatous hyperplasia depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Pseudoepitheliomatous hyperplasia)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Characterization of acne associated with upadacitinib treatment in patients with Acne associated with upadacitinib for eczema treatment is usually mild/moderate in severity and managed with applied to the skin therapies or no intervention. Journal of the American Academy of Dermatology • 2022-10-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 35714786 ↗ |
| Can This Approach Help? Inside the Latest Research on Isotretinoin and tetracycline in the management of severe nodulocystic All patients on isotretinoin experienced side effects that were primarily related to the integumentary system but necessitated discontinuation of the drug for a short period of time in only one patient. International journal of dermatology • 1985-05-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 3159698 ↗ |
| What the Latest Evidence Really Says About Association between eczema and high blood AD, particularly moderate-to-severe disease, was associated with increased high blood pressure compared with healthy controls, but with lower odds than for psoriasis. The British journal of dermatology • 2022-02-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 34319589 ↗ |
| What the Latest Evidence Really Says About Association between psoriasis and hair loss This study suggests a bidirectional association between psoriasis and hair loss areata. The Journal of dermatology • 2022-09-15 • Meta-Analysis | Multi-cohort | 86/100 | PMID 35510645 ↗ |
| Can This Approach Help? Inside the Latest Research on Tretinoin Loaded Nanoemulsion for Acne Vulgaris: Fabrication, Physicochemical and In a pilot clinical study, the number of acne lesions as well as the size and intensity of porphyrin production significantly reduced after applied to the skin application of NE-TRE. Skin pharmacology and physiology • 2018-01-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 30199861 ↗ |
Pseudoepitheliomatous hyperplasia Patient Community & “People Like Me” Threads
Filter Pseudoepitheliomatous hyperplasia community threads and patient logs by age, biological sex, dosage, and treatment duration.